Bicycle Therapeutics (NASDAQ:BCYC) Upgraded at Wall Street Zen

Posted by Brenda Bartman on Nov 3rd, 2026

Wall Street Zen upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) from a sell rating to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.

BCYC has been the subject of several other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, October 2nd. Jefferies Financial Group restated a “buy” rating and issued a $10.00 target price on shares of Bicycle Therapeutics in a research report on Thursday. Zacks Research cut shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Finally, Needham & Company LLC lowered their price target on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Bicycle Therapeutics has an average rating of “Hold” and a consensus price target of $13.57.

Read Our Latest Stock Report on Bicycle Therapeutics

Bicycle Therapeutics Price Performance

BCYC stock opened at $3.62 on Friday. Bicycle Therapeutics has a 12 month low of $3.33 and a 12 month high of $8.11. The firm has a 50-day moving average price of $3.82 and a 200-day moving average price of $4.57.

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.25. The company had revenue of $34.06 million for the quarter, compared to the consensus estimate of $12.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. On average, analysts anticipate that Bicycle Therapeutics will post -2.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Bicycle Therapeutics by 512.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after purchasing an additional 6,447 shares during the last quarter. Portland Investment Counsel Inc. bought a new position in Bicycle Therapeutics during the second quarter worth $64,000. Royal Bank of Canada raised its stake in Bicycle Therapeutics by 35.5% during the first quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock worth $67,000 after buying an additional 3,788 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in Bicycle Therapeutics by 15.0% in the third quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company’s stock valued at $85,000 after buying an additional 3,000 shares during the period. Finally, R Squared Ltd acquired a new position in Bicycle Therapeutics in the first quarter valued at $98,000. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

(Get Free Report)

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.